Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Cardiovasc Ther. 2012 Oct;10(10):1251-60. doi: 10.1586/erc.12.128. Epub 2012 Oct 31.

Standardization of outcome measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm.

Author information

  • 1Cardiovascular Science Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. xingli.wang@novartis.com

Abstract

An abdominal aortic aneurysm (AAA) is a common aortic wall disease with an increased prevalence in the elderly population (4-8% for those aged >65 years). Many AAAs are slow growing and remain insidious. Current standard of care for patients with small AAAs (<49 mm) is surveillance, with interventional therapy (open surgical repair or endovascular aneurysm repair) recommended for large (>50-55 mm), rapidly growing (>10 mm/year) or symptomatic AAAs. Although open surgical repair or endovascular aneurysm repair are effective, significant short- and long-term postoperative morbidity and mortality occurs. Currently, there is no pharmacological treatment specific for AAA; the need for the development of targeted pharmacological therapies based on clinically relevant and feasible outcomes acceptable to the medical community, regulatory agencies and third-party payers is high. A consensus on such end points will be critical to accelerating the development of pharmacological agents to prevent formation, arrest the expansion and reduce the rupture risk of AAA.

PMID:
23113642
DOI:
10.1586/erc.12.128
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center